LV 12250

(19) LATVIJAS REPUBLIKAS
PATENTU VALDE

(11) LV 12250 B

(51) Int.Cl. [6] A61K31/195
A61K9/20
A61K47/02

Latvijas patents uz izgudrojumu
1995.g. 30.marta Latvijas Republikas likums

(12) Īsziņas

(21) Pieteikuma numurs: P-98-269

(22) Pieteikuma datums: 17.11.1998

(41) Pieteikuma publikācijas datums: 20.04.1999

(45) Patenta publikācijas datums: 20.09.1999

(30) Prioritāte:
MI96A000992 17.05.1996 IT

(86) PCT pieteikums:
PCT/EP97/02709, 15.05.1997

(87) PCT publikācija:
WO 97/44023, 27.11.1997

(73) Īpašnieks(i):
APR PATENT HOLDER S.A.; Centre Vermont, L-2449 8, boulevard Royal, LU

(72) Izgudrotājs(i):
Alberto REINER (IT),
Giorgio REINER (IT)

(74) Pilnvarotais vai pārstāvis:
Armīns PĒTERSONS,
Aģentūra "PĒTERSONA PATENTS",
a/k 61, Rīga LV-1010, LV

(54) Virsraksts: **Farmaceitiskas kompozīcijas uz diklofenaka bāzes**

(57) Kopsavilkums: Aprakstītas jaunas farmaceitiskas kompozīcijas perorālai lietošanai, kas satur diklofenaku kopā ar sārmu metālu karbonātiem un bikarbonātiem, un specifiskām aromatizētājvielām. Šādas kompozīcijas ir patīkamas un brīvas no jebkādas nepatīkamas garšas vai citiem blakus efektiem.

IZGUDROJUMA FORMULA

1. Farmaceitiska kompozīcija perorālai lietošanai, kas satur diklofenaku skābes un/vai sāls formā kopā ar sārmu metālu bikarbonātiem vai to maisījumiem un parastām pildvielām un palīgvielām, **atšķiras ar to,** ka minētie sārmu metālu bikarbonāti ir daudzumā no 20 līdz 80 masas %, izejot no diklofenaka masas.

2. Kompozīcija saskaņā ar 1. punktu, kas **atšķiras ar to,** ka minētie sārmu metālu bikarbonāti ir kālija un/vai nātrija bikarbonāti.

3. Kompozīcija saskaņā ar 1. punktu, kas **atšķiras ar to,** ka diklofenaks ir tā kālija un/vai nātrija sāls formā un ka minētie sārmu metālu bikarbonāti ir kālija un/vai nātrija bikarbonāti.

4. Kompozīcija saskaņā ar 1. punktu, kas **atšķiras ar to,** ka tā satur vismaz vienu aromatizētājvielu, kas izvēlēta no piparmētras, anīsa sēklas un amonija glicirizināta.

5. Kompozīcija saskaņā ar 4. punktu, kas **atšķiras ar to,** ka minētā vismaz viena aromatizētājviela ir tīrā veidā no 1/5 līdz 3-kārtīgam masas daudzumam, izejot no diklofenaka masas.

6. Sārmu metālu bikarbonātu vai to maisījumu izmantošana kopā ar parastām pildvielām un palīgvielām farmaceitisku kompozīciju iegūšanai perorālai lietošanai, kas satur diklofenaku skābes formā un/vai sārmu metālu sāls formā, **atšķiras ar to,** ka minētie sārmu metālu bikarbonāti ir daudzumā no 20 līdz 80 masas %, izejot no diklofenaka masas.

7. Izmantošana saskaņā ar 6. punktu, kas **atšķiras ar to,** ka minētie sārmu metālu bikarbonāti ir kālija un/vai nātrija bikarbonāti.

8. Izmantošana saskaņā ar 6. punktu, kas **atšķiras ar to,** ka minētie sārmu metālu bikarbonāti ir kālija un/vai nātrija bikarbonāti un ka diklofenaks ir tā kālija un/vai nātrija sāls formā.

9. Izmantošana saskaņā ar 6. punktu, kas **atšķiras ar to,** ka vismaz viena aromatizētājviela, kas izvēlēta no piparmētras, anīsa sēklas un amonija glicirizināta, ir izmantota kombinācijā ar minētajiem sārmu metālu bikarbonātiem vai to maisījumiem dažādās šo sāļu proporcijās.

10. Izmantošana saskaņā ar 9. punktu, kas **atšķiras ar to,** ka minētā vismaz viena aromatizētājviela ir tīrā veidā no 1/5 līdz 3-kārtīgam masas daudzumam, izejot no diklofenaka masas.

FIG. 1


KĀLIJA DIKLOFENAKS
Kompozīcija A -
pg/ml
4000
3500
3000
2500
2000
1500
1000
500
0
0
20
40
60
80
100
120
140
160
180
200
220
240
Laiks (min)
V1-Komp. A
V2 - Komp. A
V3 - Komp. A
V4-Komp. A
V5-Komp. A
V6-Komp. A

FIG. 2


KĀLIJA DIKLOFENAKS
Kompozīcija B -
pg/ml
0
500
1000
1500
2000
2500
3000
3500
4000
Laiks (min)
0
20
40
60
80
100
120
140
160
180
200
220
240
V1- Komp. B
V2- Komp. B
V3 - Komp. B
V4-|Komp. B
V5-Komp. B
V6- Komp. B

FIG. 3


KĀLIJA DIKLOFENAKS
Kompozicija C -
μg/ml
4000
3500
3000
2500
2000
1500
1000
500
0
0
20
40
60
80
100
120
140
160
180
200
220
240
Laiks (mln)
V1- Komp. C
V2 - Komp. C
V3 - Komp. C
V4-Komp. C
V5-Komp. C
V6-Komp. C

FIG. 4


KĀLIJA DIKLOFENAKS
Kompozīcija A - 6 brīvu mērījumu vidējais lielums
pg/ml
4000
3500
3000
2500
2000
1500
1000
500
0
0
20
40
60
80
100
120
140
160
180
200
220
240
laiks (mln)
Vide ±D.S.

FIG. 5


KĀLIJA DIKLOFENAKS
Kompozīcija B - 6 brīvu mērījumu vidējais lielums
pg/ml
4000
3500
3000
2500
2000
1500
1000
500
0
0
20
40
60
80
100
120
140
160
180
200
220
240
laiks (mln)
Vide ±D.S.

FIG. 6

KĀLIJA DIKLOFENAKS

Kompozīcija C - 6 brīvu mērījumu vidējais lielums



FIG. 7


KĀLIJA DIKLOFENAKS
Kompozīcija A - B - C - 6 brīvu mērījumu vidējais lielums
µg/ml
4000
3500
3000
2500
2000
1500
1000
500
0
0
20
40
60
80
100
120
140
160
180
200
220
240
laiks (mln)
Komp. A
Komp. B
Komp. C

Pharmaceutical compositions based on diclofenac

The present invention relates to new pharmaceutical compositions containing [(2,6-dichloro-anilino)-2-phenyl]-2-acetic acid (more commonly known as diclofenac) in acid and/or salt form.

Diclofenac is a non-steroidal drug which is widely dispensed and used owing to its well-known analgesic, anti-pyretic, anti-arthritic, anti-phlogistic and anti-rheumatic properties; its structural formula is indicated below.



Diclofenac is generally taken orally in the form of normal tablets or tablets covered with coatings resistant to gastric juices, or rectally, or by injection, or topically.

The possibility of taking it in the form of sweets, tablets dissolving in the mouth, drages, chewing gum or other similar pharmaceutical forms or in formulations for the extemporary preparation of diclofenac-based aqueous solutions and/or suspensions would represent a different mode of administration which is definitely more suitable, especially for children and elderly persons.

Owing to its poor solubility in water, diclofenac is normally used in salt form; the salts of diclofenac customarily used are those of sodium, potassium or other alkali and alkaline earth metals, together with salts of organic nature, such as the salts of basic amino acids, such as lysine, arginine and ornithine, or other pharmacologically acceptable organic bases which have the ability to render the resulting salt soluble in water.

The pharmaceutical compositions of the diclofenac salts for oral use are generally accompanied by side effects of not inconsiderable consequence.

Diclofenac salts are characterised by a particularly unpleasant and bitter taste and by the fact that they produce a sensation of strong astringency and cause an

especially intense form of irritation in the buccal cavity, especially in the area of the larynx.

Although the first problem has been partly solved by using flavourings which are able in some manner to mask the taste, satisfactory solutions have still not been proposed for the two remaining problems.

Therefore, the pharmaceutical compositions containing diclofenac salts still have a poor palatability which limits their adoption and possible fields of application, despite the excellent therapeutic effect with which they are associated.

The subject of the present invention is that it has now surprisingly been found that, by adding alkali metal carbonates and bicarbonates or mixtures thereof to the diclofenac salts, together with customary excipients and adjuvants, pharmaceutical compositions can be obtained which are for the most part free from the side effects mentioned above and especially from the astringent sensation in the area of the larynx.

The amount of such inorganic salts added to the compositions containing diclofenac is from 20 to 80 % by weight, based on the weight of the acid-form diclofenac.

In the preferred embodiment of the present invention, the inorganic salts are selected from sodium and potassium carbonates and bicarbonates.

It has also been found, and forms a second subject of the present invention, that the addition of flavouring substances selected from mint, aniseed, ammonium glycyrrhizinate and mixtures thereof to the compositions containing the diclofenac salts and alkali metal carbonates and/or bicarbonates produces a synergistic effect which completely eliminates all the above-mentioned side effects, providing pharmaceutical compositions which are entirely palatable (and/or drinkable in the case of those used for the preparation of solutions and/or suspensions) and free from aftertaste.

It has now surprisingly been found that the use of alkali metal carbonates and/or bicarbonates for the preparation of the compositions of the present invention permit constant, reproducible and foreseeable blood levels of the active ingredient,

as it will be clear from example 5, with the consequent indisputable advantages from the therapeutic point of view.

Finally, it has also surprisingly been found that the combined use of alkali metal carbonates and/or bicarbonates and the above-mentioned flavouring substances yields diclofenac-based pharmaceutical compositions in which the active ingredient is released more rapidly compared with normal formulations, bringing about higher blood levels and therefore a more immediate therapeutic effect.

The flavouring substances may be used as such or supported on inert materials, for example maltodextrin, in order to obtain a better distribution of the granulates and to facilitate excellent dispersibility of the flavouring in solution. Preferably, they are absorbed on maltodextrin with a power of 1 to 2000 and 1 to 1000.

The amount of flavouring substances in its pure form is also preferably from 1/5 to 3 times the weight of the acid-form diclofenac.

These flavouring substances are used in the implementation of the present invention without altering their organoleptic properties and without depriving them of their intrinsic qualities of flavourings which are liposoluble and generally oily in the pure state.

The following Examples are given purely by way of non-limiting illustration.

Example 1 - Composition dissolving instantly in water

- Active ingredients

1) Diclofenac potassium salt* :	50 mg
2) Potassium bicarbonate:	22 mg
3) Mint flavouring on maltodextrin(1:2000)**:	60 mg
4) Aniseed flavouring on maltodextrin (1:1000)***:	104 mg
- Excipients and adjuvants	
5) Saccharin:	4 mg
6) Aspartame:	10 mg
7) Mannitol:	50 mg
8) Saccharose*** *q.s.:	2 g

* If it is desired to prepare compositions based on diclofenac sodium salt, it is

advantageous to use sodium bicarbonate in a quantity of approximately 38% by weight based on the weight of the diclofenac sodium salt present.

Sodium carbonate may also be added to the sodium bicarbonate, maintaining the following optimum proportions: 27 % of sodium bicarbonate and 4-5 % of sodium carbonate, always based on the amount by weight of diclofenac sodium salt present.

** The title of the pure mint essence, as obtained according to the Dean-Stark method, is of 18% by weight; the related amount is therefore in this case of 10.8 mg.

*** The title of the pure anise essence, as obtained according to the Dean-Stark method, is of 14.5% by weight, the related amount is therefore in this case of 16 mg.

**** The presence of saccharose is not strictly necessary; in its absence, a composition having a very limited granulate content is obtained which is perfectly soluble in contact with water. In that case, nothing is changed from the point of view of tolerability in contact with the mucosa and from the point of view of the palatability of the drinkable solution.

- Preparation

Components 1, 2, 5, 6 and 7 are mixed in a suitable mixer, and the mixture so obtained is wetted with 95% ethanol. Granulation is carried out with a 66 mm mesh and the granulate is preferably dried in a current of air.

Components 3, 4 and 8, which have already been granulated using a mesh of the same granulometry, are then added and the whole is mixed.

The mixture is then introduced into a metering machine filling packets or similar containers.

Example 2 - Effervescent composition

- Active ingredients

1) Diclofenac potassium salt*:	50 mg
2) Potassium bicarbonate:	24 mg
3) Mint flavouring on maltodextrin (1:2000)**:	50 mg

4) Aniseed flavouring on maltodextrin (1:1000)***:	120 mg
- Excipients and adjuvants	
5) Potassium bicarbonate:	780 mg
6) Saccharin:	5 mg
7) Mannitol:	65 mg
8) Citric acid:	500 mg
9) Aspartame:	9 mg
10) Saccharose**** q.s.:	3 g

* to**** see Example 1

- Preparation

Components 1, 2, 5, 6, 7 and 9 are mixed in a suitable mixer, and the mixture so obtained is wetted with 95 % ethanol. Granulation is carried out using a 66 mm mesh and the granulate is preferably dried in a current of air.

Components 3, 4, 8 and 10, which have already been granulated using a mesh of the same granulometry, are then added and the whole is mixed.

The mixture is then introduced into a metering machine filling packets or similar containers in a dehumidified chamber.

Example 3 - Tablet for dissolving in the mouth

- Active ingredients	
1) Diclofenac potassium salt*:	50 mg
2) Potassium bicarbonate:	35 mg
3) Mint flavouring on maltodextrin** (1:2000) + gum arabic (E 414):	50 mg
4) Aniseed flavouring (1:1000) on maltodextrin*** + silicon dioxide (E 551):	120 mg
- Excipients and adjuvants	
5) Saccharin:	50 mg
6) Aspartame:	12 mg
7) Mannitol:	20 mg

8) Saccharose****: 300 mg

* to**** see Example 1

Example 4 - Gum tablet

- Active ingredients

1) Diclofenac potassium salt*: 50 mg

2) Potassium bicarbonate: 35 mg

3) Mint flavouring on maltodextrin**: 30 mg

4) Aniseed flavouring on maltodextrin***: 80 mg

- Excipients and adjuvants

5) Mannitol: 30 mg

6) Menthol: 0.010 mg

7) Gum base: 600 mg

8) Sorbitol: 700 mg

9) Saccharin: 3 mg

10) Hydroxypropylmethylcellulose: 33 mg

11) Colouring agent: 7 mg

* to*** see Example 1

Example 5 - Comparative test

The packaged composition containing 50 mg of diclofenac potassium of Example 1 (formulation C) was subjected to a pharmacokinetic test for comparison with a similar composition not containing alkali metal carbonates and bicarbonates (formulation B), and with a second composition in tablet form (formulation A) produced by Ciba-Geigy (Voltaren Rapid ®), also in this case not containing alkali metal carbonates and bicarbonates, both formulations A and B containing 50 mg of diclofenac potassium.

This comparative evaluation was carried out on the same 6 healthy volunteers in accordance with the experimental plan described hereinafter.

- Experimental scheme: Single-dose study using three methods in randomised cross- over with a wash-out of three days.

- Sampling times: 0h (before administration), 5 min, 10 min, 30 min, 45 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, after each administration.
- Blood sample treatment: 8MI in heparinised test tubes, centrifugation for 15 min at 1500 rev/min, subdivided into two fractions and subsequently frozen at -20°C.
- Times: wash-out of two days between treatments.
- Determination method: HPLC, with internal standard, sensitivity 10 ng/ml.

Analysis method

- Column: Nova Pak C18, 3.9x150 mm, 4 μm Waters S.p.A. - Vimodrone, Italy.
- Eluant: NaH2PO4 0.01 M + 0.1 % TEA, pH 3.0 (H3PO4)/acetonitrile, 60/40.
- Flow: 1.2 ml/min
- Detection: UV/275 nm
- Temperature: 30°C
- Injection: 50 al
- Analysis time: 16 min.

Sample preparation

10 al of the internal standard methanolic solution, and flufenamic acid (corresponding to

1320 ng) are added to 1 ml of defrosted plasma in 10 ml glass test tubes. The tubes are agitated in a Vortex mixer for 1 minute. 0.5 ml of a 0.5N HCl/1N NaCl solution is added. The whole is agitated in a Vortex mixer for 1 minute. 6 ml of a 95/5 n-hexane/isopropanol solution are added.

The mixture is then agitated in the Vortex mixer for a further 15 minutes. Centrifugation is carried out at 3000 rev/min for 15 minutes and the organic phase is transferred to fresh 10 ml glass test tubes and evaporated to dryness in a centrifugal evaporator under vacuum at ambient temperature. The whole is taken up in 200 al of a 70/30 acetonitrile/water solution, and the precipitate is dissolved under ultrasound for 2 minutes.

Figures 1, 2 and 3 show the concentrations of diclofenac in the blood of the six volunteers as regards formulations A, B (Ciba-Geigy comparative formulations) and C (formulation corresponding to the composition of Example 1), respectively.

As will be appreciated, the blood concentration of the formulation of the present invention has, compared with the comparative formulations, a more constant and uniform pattern. This characteristic is also found in Figures 4, 5 and 6 which show the average values corresponding to the blood levels of the six volunteers together with the corresponding standard deviation.

The result is clear and surprising: compared with the sample compositions, the compositions of the present invention permit constant, reproducible and foreseeable blood levels of the active ingredient, irrespective of the characteristics of the volunteer (weight, age, etc), with the consequent indisputable advantages from the therapeutic point of view.

Finally, Figure 7 shows, by comparison, the graphs relating to the average values of the six volunteers (that is to say, the preceding Figures 4, 5 and 6); as will be noted, the formulation of the present invention permits, in addition to the advantages already mentioned, the attainment of a blood peak higher than that of the other formulations.

Example 6 - Two layered tablet (fast and slow release)

Fast release layer

1) Diclofenac potassium salt:	30 mg
2) Potassium bicarbonate:	30 mg
3) Lactose:	13.2 mg
4) Maize starch (intragranular):	6 mg
5) Methyl cellulose:	0.12 mg
6) Sodium laurylsulfate:	0.06 mg
7) Maize starch (extragranular):	9 mg
8) Crospovidone:	0.6 mg
9) Sodium carboxtmethylstarch:	1.5 mg
10) Magnesium stearate:	2.7 mg
11) Colloidal silicon dioxide:	0.6 mg

Slow release layer

1) Diclofenac potassium salt:	70 mg

2) Potassium bicarbonate:	30.8 mg
3) Lactose:	32.2 mg
4) Polyvinylpyrrolidone:	1.16 mg
5) Hydrpxypropylmethylcellulose:	70 mg
6) Magnesium stearate:	0.84 mg
7) Colloidal silicon dioxide:	0.21 mg
8) Talc:	3.92 mg
9) Polyethylene glycol:	0.56 mg

Example 7 - Drops

1) Diclofenac potassium salt:	75 g
2) Methyl p-oxybenzoate:	2.7 g
3) Propyl p-oxybenzoate:	0.3 g
4) Aspartame:	37.5 g
5) Potassium bicarbonate:	37.5 g
6) Glycerol:	300 g
7) Ethyl alcool:	450 g
8) Water q.s.:	1500 g

Possible modifications:

a) Addition of sodium metabisulfite (0.06%)

b) Addition of sodium metabisulfite (0.06%)
Mint flavouring (1.25%)
Strawberry flavouring (0.75%)

Example 8 - Drops

1) Diclofenac potassium salt:	37.5 g
2) Methyl p-oxybenzoate:	2.7 g
3) Propyl p-oxybenzoate:	0.3 g
4) Aspartame:	37.5 g
5) Potassium bicarbonate:	18.75 g
6) Saccharin:	6.0 g
7) Glycerol:	300 g

8) Ethyl alcool:	450 g
9) Water q.s.:	1500 g

Possible modifications:

a) Addition of sodium metabisulfite (0.03%)

b) Addition of sodium metabisulfite (0.03%)

Mint flavouring (1.25%)

Strawberry flavouring (0.75%)

Example 9 - Mouthwash

1) Diclofenac potassium salt:	0.75 g
2) Glycerol:	50 g
3) Sorbitol:	12 g
4) Saccharin:	0.5 g
5) Aspartame:	1.0 g
6) Methyl p-oxybenzoate:	0.5 g
7) Propyl p-oxybenzoate:	0.1 g
8) Mint flavouring:	1.0 g
9) Ethyl alcool:	100 g
10) Potassium bicarbonate:	0.33 g
11) Water q.s.:	500 ml

Example 10 - Gum-paste

1) Diclofenac potassium salt:	5.0 g
2) Glycerol:	630 g
3) Sodium benzoate:	5.0 g
4) Silica (Wessalon S® - Degussa):	120 g
5) Silica (Siddent 9® - Degussa):	80 g
6) Cellulose gum:	3.0 g
7) Polyethylenglycol 600:	30 g
8) Sodium lauroyl sarcosinate (or sodium lauryl sulfate):	60 g
9) Mint flavouring:	10 g
10) Sodium saccharin:	1.0 g

11) Aspartame:	3.0 g
12) Potassium bicarbonate:	2.2 g
13) Water q.s.:	1 kg

Example 11 - Tooth-paste

1) Diclofenac potassium salt:	5.0 g
2) Glycerol:	630 g
3) Sodium benzoate:	5.0 g
4) Silica (Wessalon S® - Degussa):	20 g
5) Silica (Siddent 9® - Degussa):	80 g
6) Cellulose gum:	3.0 g
7) Polyethylenglycol 600:	30 g
8) Sodium lauroyl sarcosinate (or sodium lauryl sulfate):	60 g
9) Mint flavouring:	10 g
10) Sodium saccharin:	1.0 g
11) Aspartame:	3.0 g
12) NaF:	1.0 g
13) Na_2FPO_3:	4.0 g
14) Potassium bicarbonate:	2.2 g
15) Water q.s.:	1 kg

Example 12 - Tablet

1) Diclofenac potassium salt:	50 mg
2) Mannitol:	50 mg
3) Potassium bicarbonate:	22 mg
4) Maize starch (intragranular):	10 mg
5) Methyl cellulose:	0.2 mg
6) Sodium laurylsulfate:	0.1 mg
7) Maize starch (extragranular):	15 mg
8) Crospovidone:	1.0 mg
9) Sodium carboxymethylstarch:	2.5 mg
10) Magnesium stearate:	4.5 mg

11) Colloidal silicon dioxide: 10 mg

CLAIMS

1. A pharmaceutical formulation for oral use containing diclofenac in acid and/or salt form together with alkali metal bicarbonates or mixtures thereof and customary excipients and adjuvants, characterized in that said alkali metal bicarbonates are present in an amount of form 20 to 80 % by weight based on the weight of diclofenac.

2. A formulation according to claim 1 characterized in that said alkali metal bicarbonates are potassium and/or sodium bicarbonates.

3. A formulation according to claim 1 characterized in that diclofenac is present in its potassium and/or sodium salt form and in that said alkali metal bicarbonates are potassium and/or sodium bicarbonates.

4. A formulation according to claim 1 characterized in that they contain at least one flavouring substance selected from mint, aniseed and ammonium glycyrrhizinate.

5. A formulation according to claim 4 characterized in that said at least one flavouring substance is present in pure form in an amount of from 1/5 to 3 times by weight based on the weight of diclofenac.

6. Use of alkali metal bicarbonates or mixtures thereof together with customary excipients and adjuvants for the preparation of pharmaceutical compositions for oral use containing diclofenac in acid form and/or in alkali metal salt form, characterized in that said alkali metal bicarbonates are present in an amount of from 20 to 80 % by weight based on the weight of diclofenac.

7. Use according to claim 6 characterized in that said alkali metal bicarbonates are potassium and/or sodium bicarbonates.

8. Use according to claim 6 characterized in that said alkali metal bicarbonates are potassium and/or sodium bicarbonates and in that diclofenac is present in its potassium and/or sodium salt form.

9. Use according to claim 6 characterized in that at least one flavouring substance selected from mint, aniseed and ammonium glycyrrhizinate is used in combination with said alkali metal bicarbonates or mixtures thereof in various ratios of these salts.

10. Use according to claim 9 characterized in that said at least one flavouring substance is present in pure form in an amount of from 1/5 to 3 times by weight based on the weight of diclofenac.

ABSTRACT

New pharmaceutical compositions for oral use containing diclofenac together with alkali metal carbonates and bicarbonates and particular flavouring substances are described. These compositions are entirely palatable and free from any unpleasant taste or other side effects.

FIG. 1


POTASSIUM DICLOFENAC
Formulation A-
pg/ml
Time (min)
V1-Form.A
V2 - Form.A
V3 - Form.A
V4-Form. A
V5-Form.A
V6-Form.A

FIG. 2


POTASSIUM DICLOFENAC
Formulation B -
µg/ml
4000
3500
3000
2500
2000
1500
1000
500
0
0
20
40
60
80
100
120
140
160
180
200
220
240
time (min)
V1-Form. B
V2-Form. B
V3 - Form. B
V4-Form. B
V5-Form. B
V6-Form. B

FIG. 3


POTASSIUM DICLOFENAC
Formulation C -
µg/ml
4000
3500
3000
2500
2000
1500
1000
500
0
0
20
40
60
80
100
120
140
160
180
200
220
240
time (mln)
V1-Form. C
V2 - Form. C
V3 - Form. C
V4-Form. C
V5-Form. C
V6-Form. C

FIG. 4


POTASSIUM DICLOFENAC
Formulation A - Average Value of the 6 volunteers
pg/ml
4000
3500
3000
2500
2000
1500
1000
500
0
0
20
40
60
80
100
120
140
160
180
200
220
240
time (min)
Media±D.S.

FIG. 5


POTASSIUM DICLOFENAC
Formulation B - Average Value of the 6 volunteers
pg/ml
4000
3500
3000
2500
2000
1500
1000
500
0
0
20
40
60
80
100
120
140
160
180
200
220
240
time (min)
Media±D.S.

FIG. 6


POTASSIUM DICLOFENAC
Formulation C - Average Value of the 6 volunteers
pg/ml
4000
3500
3000
2500
2000
1500
1000
500
0
0
20
40
60
80
100
120
140
160
180
200
220
240
time (min)
Media±D.S.

FIG. 7


POTASSIUM DICLOFENAC
Formulation A - B - C - Average Value of the 6 volunteers
ng/ml
4000
3500
3000
2500
2000
1500
1000
500
0
0
20
40
60
80
100
120
140
160
180
200
220
240
time (min)
Form. A
Form. B
Form. C